These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25527998)

  • 1. Moderators of response to cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care.
    Button KS; Turner N; Campbell J; Kessler D; Kuyken W; Lewis G; Peters TJ; Thomas L; Wiles N
    J Affect Disord; 2015 Mar; 174():272-80. PubMed ID: 25527998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial.
    Wiles N; Thomas L; Abel A; Barnes M; Carroll F; Ridgway N; Sherlock S; Turner N; Button K; Odondi L; Metcalfe C; Owen-Smith A; Campbell J; Garland A; Hollinghurst S; Jerrom B; Kessler D; Kuyken W; Morrison J; Turner K; Williams C; Peters T; Lewis G
    Health Technol Assess; 2014 May; 18(31):1-167, vii-viii. PubMed ID: 24824481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial.
    Wiles NJ; Thomas L; Turner N; Garfield K; Kounali D; Campbell J; Kessler D; Kuyken W; Lewis G; Morrison J; Williams C; Peters TJ; Hollinghurst S
    Lancet Psychiatry; 2016 Feb; 3(2):137-44. PubMed ID: 26777773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial.
    Wiles N; Thomas L; Abel A; Ridgway N; Turner N; Campbell J; Garland A; Hollinghurst S; Jerrom B; Kessler D; Kuyken W; Morrison J; Turner K; Williams C; Peters T; Lewis G
    Lancet; 2013 Feb; 381(9864):375-84. PubMed ID: 23219570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: the CoBalT randomised controlled trial protocol.
    Thomas LJ; Abel A; Ridgway N; Peters T; Kessler D; Hollinghurst S; Turner K; Garland A; Jerrom B; Morrison J; Williams C; Campbell J; Kuyken W; Lewis G; Wiles N
    Contemp Clin Trials; 2012 Mar; 33(2):312-9. PubMed ID: 22101205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial.
    Hollinghurst S; Carroll FE; Abel A; Campbell J; Garland A; Jerrom B; Kessler D; Kuyken W; Morrison J; Ridgway N; Thomas L; Turner K; Williams C; Peters TJ; Lewis G; Wiles N
    Br J Psychiatry; 2014 Jan; 204(1):69-76. PubMed ID: 24262818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings.
    Sado M; Koreki A; Ninomiya A; Kurata C; Mitsuda D; Sato Y; Kikuchi T; Fujisawa D; Ono Y; Mimura M; Nakagawa A
    Psychiatry Clin Neurosci; 2021 Nov; 75(11):341-350. PubMed ID: 34459077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial.
    Nakagawa A; Mitsuda D; Sado M; Abe T; Fujisawa D; Kikuchi T; Iwashita S; Mimura M; Ono Y
    J Clin Psychiatry; 2017; 78(8):1126-1135. PubMed ID: 28252882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
    Dunlop BW; LoParo D; Kinkead B; Mletzko-Crowe T; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
    Am J Psychiatry; 2019 Apr; 176(4):275-286. PubMed ID: 30764648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards personalising treatment: a systematic review and meta-analysis of face-to-face efficacy moderators of cognitive-behavioral therapy and interpersonal psychotherapy for major depressive disorder.
    Whiston A; Bockting CLH; Semkovska M
    Psychol Med; 2019 Dec; 49(16):2657-2668. PubMed ID: 31615583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severity of panic disorder, adverse events in childhood, dissociation, self-stigma and comorbid personality disorders Part 2: Therapeutic effectiveness of a combined cognitive behavioural therapy and pharmacotherapy in treatment-resistant inpatients.
    Kolek A; Prasko J; Ociskova M; Holubova M; Vanek J; Grambal A; Slepecky M
    Neuro Endocrinol Lett; 2019 Dec; 40(6):271-283. PubMed ID: 32200586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial.
    Richards DA; Ekers D; McMillan D; Taylor RS; Byford S; Warren FC; Barrett B; Farrand PA; Gilbody S; Kuyken W; O'Mahen H; Watkins ER; Wright KA; Hollon SD; Reed N; Rhodes S; Fletcher E; Finning K
    Lancet; 2016 Aug; 388(10047):871-80. PubMed ID: 27461440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding smartphone-based cognitive-behavior therapy to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled trial.
    Watanabe N; Horikoshi M; Yamada M; Shimodera S; Akechi T; Miki K; Inagaki M; Yonemoto N; Imai H; Tajika A; Ogawa Y; Takeshima N; Hayasaka Y; Furukawa TA;
    Trials; 2015 Jul; 16():293. PubMed ID: 26149441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional Beliefs of Primary-Care Patients with Treatment-Resistant Depression.
    Burrage A; Green S; Turner K; Kuyken W; Williams C; Wiles N; Lewis G
    Behav Cogn Psychother; 2016 Sep; 44(5):513-26. PubMed ID: 26530496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.
    Kennedy TM; Chalder T; McCrone P; Darnley S; Knapp M; Jones RH; Wessely S
    Health Technol Assess; 2006 Jun; 10(19):iii-iv, ix-x, 1-67. PubMed ID: 16729918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive change in cognitive-behavioural therapy
    Quigley L; Dozois DJA; Bagby RM; Lobo DSS; Ravindran L; Quilty LC
    Psychol Med; 2019 Nov; 49(15):2626-2634. PubMed ID: 30560738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of cognitive behaviour therapy for treatment-resistant depression with psychiatric comorbidity: comparison of individual versus group CBT in an interdisciplinary rehabilitation setting.
    Hauksson P; Ingibergsdóttir S; Gunnarsdóttir T; Jónsdóttir IH
    Nord J Psychiatry; 2017 Aug; 71(6):465-472. PubMed ID: 28598705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial.
    Serfaty MA; Haworth D; Blanchard M; Buszewicz M; Murad S; King M
    Arch Gen Psychiatry; 2009 Dec; 66(12):1332-40. PubMed ID: 19996038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
    Wilkinson ST; Wright D; Fasula MK; Fenton L; Griepp M; Ostroff RB; Sanacora G
    Psychother Psychosom; 2017; 86(3):162-167. PubMed ID: 28490030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and cost effectiveness of cognitive behavioural therapy plus treatment as usual for the treatment of depression in advanced cancer (CanTalk): study protocol for a randomised controlled trial.
    Serfaty M; King M; Nazareth I; Tookman A; Wood J; Gola A; Aspden T; Mannix K; Davis S; Moorey S; Jones L
    Trials; 2016 Feb; 17(1):113. PubMed ID: 26926910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.